The 340B landscape is changing again.

HRSA has announced a revised 340B Rebate Model Pilot Program that could change how participating covered entities receive 340B pricing on certain drugs. Instead of receiving the 340B discount upfront, covered entities affected by an approved manufacturer plan would purchase selected drugs at a higher upfront price and receive the 340B benefit later through a rebate after eligible claims are validated. The revised pilot is scheduled to take effect January 1, 2027, for approved manufacturer plans and applicable selected drugs. 

For 340B leaders, however, the pilot is only part of the story. Congress is simultaneously considering different approaches that could significantly alter or replace the rebate model.

In other words: three proposals, three different paths. Read more >